---
provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2026-02-01T09:56:16.747893'
end_time: '2026-02-01T10:05:08.856842'
duration_seconds: 532.11
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Renal Cell Carcinoma
  mondo_id: ''
  category: Cancer
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    top_p: 1.0
citation_count: 165
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Renal Cell Carcinoma
- **MONDO ID:**  (if available)
- **Category:** Cancer

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Renal Cell Carcinoma**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

# Renal Cell Carcinoma Pathophysiology

Renal cell carcinoma (RCC) is a malignant tumor arising from the epithelial cells of the renal tubules in the kidney (primarily the **renal cortex**, UBERON:0002314) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=RCC%20arises%20from%20epithelial%20cells,13)). It is a heterogeneous disease at both the genomic and cellular level, but clear cell renal cell carcinoma (ccRCC) is the most common subtype, accounting for ~75–80% of cases ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=The%203%20dominant%20histological%20subtypes,3p%2C%20home%20to%20VHL%2C%20as)). The pathophysiology of RCC is driven by *multi-step molecular alterations* that dysregulate key cellular pathways, leading to uncontrolled cell growth, angiogenesis, metabolic reprogramming, and immune evasion. Below, we detail the core mechanisms of RCC progression, highlighting the **genes (HGNC symbols)**, **molecular pathways (GO processes)**, **cellular components**, and resultant **clinical phenotypes (HP terms)**, with evidence from recent research and expert analyses.

## Core Pathophysiological Mechanisms

**1. Hypoxia Signaling and Angiogenesis:** The most prominent pathway in ccRCC is the dysregulation of cellular oxygen-sensing. In normal cells, the *von Hippel–Lindau (VHL)* tumor suppressor gene (HGNC:12687) encodes an E3 ubiquitin ligase component (pVHL) that targets hypoxia-inducible factor alpha (HIF-α) for degradation in the presence of oxygen ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,promoting)). *Loss of VHL function* (through mutation or chromosomal deletion on 3p) is a near-universal initiating event in ccRCC (present in up to 90% of tumors) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=%2810,inducible%20factor%20%28HIF%29%20family)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=sporadic%20disease,of%20ccRCC%20cases%20%5E%7B12)). In VHL-proficient cells under normoxia, HIF-α subunits (HIF1α and HIF2α) are proline-hydroxylated and bind pVHL, leading to their ubiquitination and proteasomal destruction ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=Under%20normal%20oxygen%20tension%2C%20HIF1A,does%20not%20occur%20and%20HIFA)). **VHL inactivation (biallelic loss)** abrogates this process – mimicking a constant hypoxic state or “*pseudohypoxia*.” Stabilized HIF-α translocates to the **nucleus** (GO:0005634) and dimerizes with HIF-1β (ARNT), functioning as a transcription factor that massively upregulates hypoxia-responsive genes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,promoting)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=and%20HIF2A%20does%20not%20occur,erythropoietin%2C%20and%20extracellular%20matrix%20proteins)). As a result, RCC cells overproduce pro-angiogenic and growth factors like **vascular endothelial growth factor A (VEGFA)**, **platelet-derived growth factor-B (PDGFB)**, and **transforming growth factor-α (TGF-α)** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,VEGFA)). These HIF target genes drive **angiogenesis (GO:0001525)** and tumor vascularization, a hallmark of ccRCC which often appears as highly vascular masses prone to hemorrhage ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=%2810,inducible%20factor%20%28HIF%29%20family)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,promoting)). HIF also induces **GLUT1** and other glycolysis enzymes to shift metabolism toward glycolysis, and stimulates **erythropoietin (EPO)** production, explaining why some RCC patients develop polycythemia (high red blood cell count) due to ectopic EPO secretion ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Common%20paraneoplastic%20manifestations%20include%20fever,patients%20after%20nephrectomy%20or%20systemic)). *In summary, the VHL/HIF pathway dysregulation is a core driver of RCC*, often termed the “engine” of ccRCC pathogenesis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=well%20as%20several%20other%20commonly,21%E2%80%9320)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,promoting)). This mechanism was first elucidated by Dr. William Kaelin and colleagues (Nobel Prize 2019) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=,Google%20Scholar)) and remains a central therapeutic target in RCC. A 2024 JAMA review emphasizes that these molecular insights have enabled therapies targeting the underlying hypoxia–angiogenesis pathophysiology ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=prevalence%20of%202.3,Box)).

**2. Tumor Suppressor Loss and Chromatin Remodeling:** In addition to VHL, several other *tumor suppressor genes* on chromosome 3p and elsewhere are frequently inactivated in RCC, contributing to tumor progression. Notably, **PBRM1** (HGNC:16289, encoding *BAF180*) is mutated in ~41% of ccRCCs ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=PBRM,expression%20of%20certain%20genes%20by)). PBRM1 is part of the SWI/SNF chromatin-remodeling complex (the PBAF complex) and helps regulate gene expression by modifying nucleosome positioning ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=PBRM,expression%20of%20certain%20genes%20by)). Loss of PBRM1 impairs normal chromatin dynamics, leading to uncontrolled cell-cycle progression (failure of cell cycle arrest) and increased proliferation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L167%20introduction%20of,23%2C%2024)). Similarly, **BAP1** (HGNC:18586, *BRCA1-associated protein 1*) is mutated in ~10–15% of ccRCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). BAP1 encodes a nuclear deubiquitinase involved in histone modification and chromatin regulation; its loss is associated with more aggressive, high-grade tumors and poorer prognosis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). Mechanistically, wild-type BAP1 forms complexes (e.g. with HCF1) that suppress cell proliferation, and BAP1 loss removes these brakes on growth ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=BRCA1,plays%20a%20role%20in%20the)). Another key gene is **SETD2** (HGNC:17076), mutated in ~10–15% of ccRCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=pathogenesis%20of%20ccRCC%20include%20VHL%2C,%5E%7B8)). SETD2 is the sole methyltransferase for histone H3 lysine 36 trimethylation (H3K36me3) and is critical for DNA damage repair and RNA splicing fidelity. SETD2 loss leads to genomic instability and altered chromatin structure. **KDM5C** (HGNC:6293), a histone demethylase, and **TP53** (HGNC:11998) or **PTEN** (HGNC:9588) are also occasionally mutated, further disrupting cell cycle control and signaling ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=has%20been%20proposed%20%283%20%29,4)). Collectively, these tumor suppressor losses result in **defective chromatin organization (GO:0006325)**, **epigenetic dysregulation (GO:0045814)** of gene expression, and loss of genome integrity, which cooperate with the VHL/HIF pathway to drive RCC progression. Notably, chromosome 3p deletions often encompass *multiple* such genes (VHL, PBRM1, BAP1, SETD2), explaining why a single early 3p loss event can knock out several tumor suppressors at once ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=pathways.,18%20%E2%80%93%2022)). The TCGA comprehensive molecular characterization (2013) showed *95% of ccRCCs have 3p loss* and recurrent mutations in these genes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=The%20most%20common%20genetic%20alteration,%5E%7B8)). Researchers have proposed an evolutionary model where **VHL loss is the truncal (first) event**, and subsequent divergence into indolent vs. aggressive subclones is partly driven by whether PBRM1 or BAP1 is lost next – BAP1 mutations tending to confer higher grade and metastatic potential ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). This sequential mutational path underlies distinct clinical trajectories within ccRCC (with PBRM1-mutant tumors often less aggressive than BAP1-mutant tumors, consistent with their prognoses ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the))).

**3. Oncogenic Signaling Pathways (PI3K/AKT/mTOR and MET):** RCC cells frequently harbor alterations in growth factor signaling pathways that promote cell survival, proliferation, and metabolism. The **PI3K–AKT–mTOR pathway** is commonly activated in RCC, either via mutations or downstream effects of the HIF pathway. The mTOR kinase (from the *MTOR* gene, HGNC:3942) is a central regulator of cell growth and metabolism. In RCC, gain-of-function mutations in *MTOR* and in components like **PIK3CA** (PI3K catalytic subunit) or loss of the PTEN tumor suppressor (a PI3K pathway inhibitor) have been reported ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=has%20been%20proposed%20%283%20%29,4)). Even in the absence of mutation, HIF overexpression can stimulate mTOR activity: HIF upregulates growth factors (like PDGF and TGF-α) that activate receptor tyrosine kinases, in turn activating PI3K/AKT signaling ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=mTOR%E2%80%93PI3K%20pathway%20starts%20with%20the,lead%20to%20the%20phosphorylation%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=,cell%20growth%20and%20tumor%20progression)). Active mTOR forms two complexes (mTORC1/2) that phosphorylate effectors such as p70S6 kinase and 4E-BP1, enhancing protein synthesis and angiogenesis (e.g. increasing VEGF and TGF-β production) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L209%20,cell%20growth%20and%20tumor%20progression)). Net effects include robust **cell proliferation (GO:0008283)**, growth, and inhibition of apoptosis. Indeed, **mTOR signaling is hyperactive in many RCCs**, and mTOR inhibitors (rapalog drugs like **temsirolimus** and **everolimus**, CHEBI:Temsirolimus) have shown clinical efficacy in metastatic RCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L221%20Everolimus%20and,line)). Another critical pathway is the **MET proto-oncogene (HGNC:7029)**, which encodes the hepatocyte growth factor receptor (HGFR). MET is especially relevant in **papillary RCC (pRCC)**, the second most common subtype (~15% of RCC). Type 1 pRCC often features activating mutations of *MET* or chromosomal gains of 7q (harboring *MET*), driving oncogenic **MET signaling** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=Papillary%20renal%20cell%20carcinoma%20,The%20following%20review%20will)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=PRCC%20is%20further%20subdivided%20into,8)). This leads to constant stimulation of the RAS–MAPK and PI3K–AKT cascades, promoting tumor cell proliferation and survival. Type 2 pRCC, in contrast, is frequently driven by alterations in genes like **CDKN2A**, **NF2**, or metabolic genes (*FH*, *SDHB*; see below) and tends to be more aggressive ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=PRCC%20is%20further%20subdivided%20into,8)). In both clear cell and non-clear cell RCC variants, dysregulated kinase signaling is a theme. For example, in some *chromophobe RCC* (a distinct subtype arising from distal tubules), mutations in **TSC1/TSC2** or the tumor suppressor *FLCN* (Folliculin, mutated in Birt–Hogg–Dubé syndrome) lead to mTOR pathway activation and abnormal metabolic signaling ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4219093/#:~:text=Abstract%20%23%23%23%20Background%20The%20Birt,to%20report%20renal%20tumour%20characteristics)). Overall, constitutive activation of pro-growth signaling pathways (via oncogenes or loss of negative regulators) is a key mechanism by which RCC cells attain autonomy from normal growth controls.

**4. Metabolic Reprogramming (“Warburg Effect” and Oncometabolites):** RCC, particularly ccRCC, has pronounced metabolic alterations. The clear-cell morphology is due to intracellular accumulation of lipids and glycogen, reflecting metabolic reprogramming. HIF-1 activation encourages a shift from oxidative phosphorylation in mitochondria to aerobic **glycolysis (GO:0006096)**, even in oxygen-replete conditions (the Warburg effect) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=and%20HIF2A%20does%20not%20occur,erythropoietin%2C%20and%20extracellular%20matrix%20proteins)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=accumulates%20and%20dimerizes%20with%20HIFB,MMP%2C%20matrix%20metalloproteinase%20protein%3B%20mRNA)). This provides rapidly dividing tumor cells with metabolic intermediates for biosynthesis. ccRCC tumors upregulate GLUT1 glucose transporters and glycolytic enzymes via HIF, increasing glucose uptake and lactate production ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=A%20total%20of%2023%20RCCs,periphery%20and%20the%20tumor%20center)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=has%20been%20proposed%20%283%20%29,4)). They also rely on **glutamine metabolism**: glutamine is converted to glutamate by *glutaminase* (GLS1), feeding the TCA cycle and providing carbon for nucleotide (pyrimidine) synthesis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=The%20glutaminase%20pathway)). In fact, VHL-deficient RCC cells exhibit *glutamine addiction*, using glutamine anaplerosis to support growth, and this is being targeted in trials (e.g. GLS inhibitor CB-839 in RCC) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L327%20under%20investigation,42%2C%2043)). Moreover, certain hereditary RCC syndromes illustrate how metabolic enzyme defects drive tumorigenesis via *oncometabolites*. For instance, *fumarate hydratase* (**FH**) mutation in **Hereditary Leiomyomatosis and RCC (HLRCC)** leads to fumarate accumulation. Excess **fumarate (CHEBI:18012)** and succinate can inhibit prolyl hydroxylase enzymes (which require α-ketoglutarate as cofactor) that normally hydroxylate HIF ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2715796/#:~:text=and%20Hypoxia,HLRCC%20are%20at%20risk%20to)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777506/#:~:text=Fumarate%20hydratase%20inactivation%20in%20renal,Article%20notes)). Thus, FH-deficient tumors also exhibit pseudohypoxia with **HIF stabilization**, much like VHL loss. Accumulated fumarate and succinate can cause *epigenetic changes* and generate reactive oxygen species (ROS), further stabilizing HIF-α and activating the NRF2 antioxidant response pathway ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777506/#:~:text=Fumarate%20hydratase%20inactivation%20in%20renal,Article%20notes)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2715796/#:~:text=in%20several%20model%20systems%2C%20and,following%20experimental%20abrogation%20of%20FH)). These metabolic derangements (captured by GO terms like **cellular metabolic process, GO:0044237**) are not mere bystanders; they are central to RCC biology. A **2019 study** showed that FH-deficient kidney cancer cells become highly dependent on *glycolysis* and ROS signaling to drive HIF activation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2715796/#:~:text=in%20several%20model%20systems%2C%20and,following%20experimental%20abrogation%20of%20FH)). Similarly, loss of *succinate dehydrogenase* (SDH) in rare RCC subsets causes succinate accumulation and HIF/NRF2 pathway upregulation (“pseudohypoxia” and oxidative stress) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777506/#:~:text=Fumarate%20hydratase%20inactivation%20in%20renal,Article%20notes)). The net effect is that RCC cells rewire metabolism to favor growth: increasing glucose and glutamine utilization, suppressing mitochondrial respiration, accumulating lipids (explaining the clear cell phenotype), and thriving in low nutrient and oxygen conditions. These metabolic vulnerabilities are being explored for therapy (e.g. **HIF-2α inhibitors**, glutaminase inhibitors, and metabolic enzyme targets).

**5. Immune Evasion and Microenvironment:** RCC has long been recognized as an “immunogenic” tumor – paradoxically, it often triggers immune cell infiltration yet manages to evade immune destruction. The *tumor microenvironment* of RCC typically contains **T lymphocytes (CL:0000084)**, including CD8+ cytotoxic T cells, as well as macrophages and other immune cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L239%20Under%20normal,These)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=immune%20response%2C%20leading%20to%20tumor,cell%20receptor)). One mechanism of immune evasion is the upregulation of immune checkpoint molecules. RCC cells commonly express **PD-L1** (programmed death-ligand 1) on their surface, which binds PD-1 receptors on T cells and inhibits T cell activity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=attacking%20and%20eliminating%20cancer,1%29%20pathway)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=activated%20by%20binding%20PD,immune%E2%80%9D)). This **PD-1/PD-L1 pathway (GO:0072626)** effectively turns off the anti-tumor immune response, allowing tumor escape. Indeed, **immune checkpoint inhibitor** therapy (antibodies against PD-1 or PD-L1, and CTLA-4) can unleash an immune attack on RCC and has led to durable remissions in a subset of patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=to%20the%20activation%20of%20cytotoxic,These)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=of%20PD,available%20are%20nivolumab%20and%20pembrolizumab)). The presence of tumor-infiltrating lymphocytes is an important feature; in fact, a 2016 genomic study found that ccRCC tumors have distinct mRNA signatures reflecting the immune microenvironment, correlating with prognosis and response to immunotherapy ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L247%20,1%2C%2034)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L564%20,z%20%5BDOI%5D%20%5BPMC)). Other immune evasion tactics include loss of MHC I expression and secretion of immunosuppressive cytokines. Furthermore, the **tumor stroma** (fibroblasts, endothelium) in RCC contributes to tumor growth – for example, carcinoma-associated fibroblasts secrete growth factors that create a pro-proliferative niche at the tumor periphery ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=Besides%20genomic%20ITH%2C%20there%20is,tumor%20cell%20proliferation%20in%20this)). The robust vascular network in RCC also means immune cells often have access to the tumor, but the tumor can create an immunosuppressive milieu to prevent effective clearance. This dynamic between RCC and the immune system underlies why high-dose IL-2 immunotherapy showed occasional complete responses historically, and why modern checkpoint inhibitors are now standard in advanced RCC. In summary, RCC pathophysiology includes an **immune component**: the cancer’s ability to **dampen cytotoxic T-cell responses (GO:0034097)** is critical for its survival, and reversing this immunosuppression has become a therapeutic cornerstone.

## Key Molecular Players and Dysregulated Pathways

RCC involves a multitude of molecular players across different biological processes. Below is a summary of the **key genes/proteins, cellular contexts, and biochemical factors** that drive RCC pathogenesis, along with their roles:

- **Von Hippel–Lindau (VHL)** – *Tumor suppressor gene (3p25)*. **Role:** Oxygen sensor via degrading HIF-α under normoxia. **Pathology:** Inactivated in most ccRCC, causing HIF accumulation and activation of hypoxia response genes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=%2810,inducible%20factor%20%28HIF%29%20family)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,promoting)). *Ontology:* located in the **cytosol** (GO:0005829) as part of the VBC ubiquitin ligase complex (with Elongins B/C, CUL2) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=The%20product%20of%20the%20VHL,the%20VHL%20gene%20product%20is)). Loss leads to constitutive **angiogenesis** and cell proliferation (via VEGF, PDGF, etc.). *Evidence:* VHL mutations are found in ~50–60% of sporadic ccRCC by conventional sequencing and up to 90% when including epigenetic silencing ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=understanding%20the%20molecular%20basis%20of,of%20ccRCC%20cases%20%5E%7B12)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=sporadic%20disease,of%20ccRCC%20cases%20%5E%7B12)). Restoring VHL in VHL-deficient RCC cells curbs their growth, underscoring its causal role ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L167%20introduction%20of,23%2C%2024)).

- **Hypoxia-Inducible Factors (HIF1α, HIF2α)** – *Transcription factors* stabilized by VHL loss or low oxygen. **Role:** Master regulators of hypoxic response; induce genes for angiogenesis, metabolic shift, and invasion. HIF2α (EPAS1, HGNC:3378) is particularly oncogenic in RCC, driving VEGF, EPO and survival pathways ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,promoting)). **Cellular location:** when active, HIFα/β dimer translocates to the nucleus to activate target genes (e.g. **VEGFA** (HGNC:12680), **PGF**, **EPO**). *Evidence:* HIF targets like **carbonic anhydrase IX (CA9)** and VEGF are highly expressed in ccRCC, and HIF2α-specific inhibitors have shown tumor regressions ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=and%20HIF2A%20does%20not%20occur,erythropoietin%2C%20and%20extracellular%20matrix%20proteins)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=accumulates%20and%20dimerizes%20with%20HIFB,MMP%2C%20matrix%20metalloproteinase%20protein%3B%20mRNA)). In fact, **belzutifan**, a small-molecule HIF-2α inhibitor, was approved in 2021 for VHL syndrome RCC and in 2023 for refractory metastatic RCC ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39926260/#:~:text=Cite%20Display%20options%20,disease%20including%20renal%20cell%20carcinoma)) ([www.merck.com](https://www.merck.com/news/fda-approves-mercks-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-rcc-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki/#:~:text=The%20approval%20is%20based%20on,6%29%20for%20everolimus)), validating HIF2 as a therapeutic target. *(Expert opinion:* Dr. Toni Choueiri noted this HIF2 inhibitor provides a “**meaningful new treatment option**” for patients who progressed on immunotherapy and anti-VEGF therapy ([www.merck.com](https://www.merck.com/news/fda-approves-mercks-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-rcc-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki/#:~:text=%E2%80%9CDespite%20recent%20progress%20in%20the,%E2%80%9D)).)*

- **PBRM1 (BAF180)** – *Chromatin remodeling complex subunit (3p21)*. **Role:** Part of PBAF SWI/SNF complex (GO:0016514) that regulates transcription by altering nucleosome positioning. **Pathology:** Second most common mutation in ccRCC (~40%). Loss of PBRM1 disrupts chromatin regulation, leading to abnormal gene expression and cell cycle progression ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=PBRM,expression%20of%20certain%20genes%20by)). *Evidence:* PBRM1-mutant RCC cells show impaired nucleosome sliding activity and are more proliferative; mutations co-occur with VHL loss and may influence tumor grade ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=PBRM,expression%20of%20certain%20genes%20by)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=introduction%20of%20PBRM,23%2C%2024)). Importantly, PBRM1 status has been linked to immune response; some studies suggest PBRM1-deficient tumors might respond differently to immunotherapy, although this is under investigation.

- **BAP1** – *Deubiquitinase enzyme (3p21)*. **Role:** Regulates histone ubiquitination and chromatin dynamics; interacts with HCF1 to control gene expression related to cell growth. **Pathology:** Mutated in ~10–15% of ccRCC, often exclusive of PBRM1 mutations ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). BAP1-mutant tumors are typically high grade, with sarcomatoid or rhabdoid features more frequently, and portend worse survival ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). *Evidence:* Germline BAP1 mutations cause a cancer syndrome with RCC, and somatic BAP1 loss in RCC is associated with increased metastasis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). Functionally, loss of BAP1 leads to uncontrolled cell proliferation due to failure to deubiquitinate H2A and other targets, disrupting normal growth arrest signals ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=BRCA1,plays%20a%20role%20in%20the)).

- **SETD2** – *Histone methyltransferase (3p21)*. **Role:** Tri-methylates H3K36 during DNA replication, important for DNA repair and transcript elongation. **Pathology:** Mutated in ~10% of ccRCC (and additional pRCC type2). Loss of SETD2 causes reduced H3K36me3 marks, impaired mismatch repair, and faulty DNA double-strand break repair. *Evidence:* SETD2 mutant RCCs have a high mutation rate and frequent chromosomal aberrations, highlighting the role of SETD2 in genomic stability. Immunohistochemistry for H3K36me3 can indicate SETD2 functional loss (low in mutant tumors) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=Unexpectedly%2C%20the%20presence%20of%20a,the%20number%20of%20driver%20mutations)). However, interestingly, one 2025 study found that SETD2 mutation didn’t always correlate with H3K36me3 levels regionally in a tumor, suggesting **intratumoral heterogeneity** in epigenetic effects ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=Unexpectedly%2C%20the%20presence%20of%20a,the%20number%20of%20driver%20mutations)).

- **MTOR and PTEN** – *Kinase and lipid phosphatase in PI3K/AKT pathway*. **Role:** mTOR promotes anabolic metabolism and cell growth; PTEN negatively regulates PI3K signaling. **Pathology:** Mutations activating mTOR (or PI3K) or inactivating PTEN occur in a subset of RCCs, especially some non-clear cell types and advanced cases ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=has%20been%20proposed%20%283%20%29,4)). Even without mutations, RCC often exhibits mTOR activation due to convergent signaling (from HIF, MET, etc.). *Evidence:* Clinicogenomic studies have attempted to correlate mTOR pathway mutations with response to mTOR inhibitor therapy; while some responding patients have mutations, many do not, indicating that mTOR activation can be driven by upstream signals in the absence of a direct mutation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=tumor%20cells,did%20not%20harbor%20mTOR%20pathway)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=stratification%20%2812%20%29,translates%20into%20corresponding%20downstream%20effects)). Regardless, the mTOR pathway is a proven therapeutic target in RCC (e.g., **temsirolimus** improved survival in poor-risk metastatic RCC in a pivotal trial, leading to its approval).

- **MET and HGFR** – *Receptor tyrosine kinase (7q31)*. **Role:** Controls cell growth, invasion, and morphogenesis in response to hepatocyte growth factor (HGF). **Pathology:** Highly relevant in papillary RCC. Hereditary pRCC (Type 1) is often caused by germline MET mutations, and sporadic pRCC frequently shows MET activation (mutations or chromosome 7 gains) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=Papillary%20renal%20cell%20carcinoma%20,The%20following%20review%20will)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=PRCC%20is%20further%20subdivided%20into,8)). MET activation triggers the RAS/ERK and PI3K pathways, overlapping with other RCC growth signals. *Evidence:* Therapeutic targeting of MET in pRCC has shown efficacy: for example, the MET inhibitor **savolitinib** demonstrated tumor responses in MET-driven pRCC, and combination of MET/VEGFR inhibitor **cabozantinib** is effective in non-ccRCC. These underscore MET as a bona fide oncogenic driver in those tumors. Type 2 pRCC lacks MET mutations but often has metabolic gene mutations (e.g. *FH*) and co-mutations in chromatin genes (similar to ccRCC), reflecting different biology ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=PRCC%20is%20further%20subdivided%20into,8)).

- **FH (Fumarate Hydratase)** and **SDH (Succinate Dehydrogenase)** – *TCA cycle enzymes*. **Role:** Mitochondrial enzymes; loss leads to oncometabolite buildup. **Pathology:** Biallelic loss of FH causes the HLRCC subtype of pRCC (aggressive type 2 pRCC); loss of SDH (SDHB/C/D subunits) causes a rare RCC variant often associated with paraganglioma syndromes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hereditary%20renal%20cancer%20syndromes%20exist,genetic%20counseling%20of%20family%20members)). *Effect:* Both result in accumulation of fumarate or succinate, which inhibit HIF prolyl hydroxylases and activate pseudohypoxia pathways (stabilizing HIF) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2715796/#:~:text=and%20Hypoxia,HLRCC%20are%20at%20risk%20to)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777506/#:~:text=Fumarate%20hydratase%20inactivation%20in%20renal,Article%20notes)). Additionally, fumarate can modify cysteine residues on proteins (succination), inactivating KEAP1 and leading to **NRF2** pathway activation (an antioxidant transcription factor). The NRF2 pathway (NFE2L2/KEAP1 mutations or oncometabolite action) is another tumor-promoting mechanism in these cancers ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=characteristic%20common%20mutations,8)). *Evidence:* Patients with germline FH mutations develop aggressive RCC early, indicating a strong oncogenic effect. Molecular studies show FH-deficient RCCs depend on glycolysis/GLUT1 (hence, “glycolytic addiction”) and generate high ROS which in turn stabilize HIF-1α ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2715796/#:~:text=in%20several%20model%20systems%2C%20and,following%20experimental%20abrogation%20of%20FH)). These tumors also demonstrate a *cachexia-like metabolic profile*, consuming glucose and glutamine avidly. Therapeutically, they are refractory to standard VEGF inhibitors, but research is ongoing into targeting metabolic vulnerabilities (e.g. HIF2 inhibitors might be less effective if HIF1 is dominant; direct metabolic enzyme therapies are explored).

- **VEGF, PDGF, TGF-α, EGFR, IL-6, etc.** – *Soluble factors and receptors*. These are not mutated drivers, but they are *key chemical mediators* in RCC’s pathology (many qualify as **chemical entities, CHEBI**). **VEGF-A** is the flagship pro-angiogenic factor induced by HIF; it diffuses in the **extracellular space (GO:0005576)** and signals via endothelial VEGF receptors to spur new blood vessel formation. **PDGF-BB** (platelet-derived growth factor) and **TGF-α** are also secreted by RCC cells under HIF/mTOR influence, acting in a paracrine fashion on stromal cells and endothelium to support angiogenesis and tumor stroma formation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,VEGFA)). These factors cause the *highly vascular tumor stroma* characteristic of RCC. Clinically, this led to development of **VEGF pathway inhibitors** (like **sunitinib, pazopanib, axitinib**, and anti-VEGF antibody **bevacizumab**). Such drugs aim to starve the tumor by blocking angiogenesis, and they have significantly improved outcomes in metastatic RCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=that%20impair%20angiogenesis%20and%20block,and%20programmed%20cell%20death)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=sunitinib%2C%20tivozanib%20%20,IV)). Other factors: **IL-6** and **IL-8** from tumor or immune cells can create an inflammatory milieu and are associated with paraneoplastic symptoms (fever, cachexia). **PTHrP** can be secreted by some RCC causing *paraneoplastic hypercalcemia*. **Renin** from juxtaglomerular cell involvement or tumor pressure can contribute to hypertension in some patients. Lastly, tumor expression of **PD-L1** (a membrane protein) is a key “molecular player” of immune escape as described above, and therapies targeting PD-1/PD-L1 have reshaped RCC management.

**Summary of dysregulated pathways:** In GO terminology, RCC is marked by aberrant activation of processes like **cellular response to hypoxia (GO:0071456)**, **angiogenesis (GO:0001525)**, **blood vessel development**, **positive regulation of cell proliferation (GO:0008284)**, **suppression of apoptotic process**, **chromatin remodeling (GO:0006338)**, **histone modification**, **gluconeogenesis/glycolysis balance**, **glutamine metabolic process**, and **immune response modulation**. The convergence of genetic mutations (VHL, PBRM1, etc.) and microenvironment interactions leads to *self-sustaining feedback loops*: e.g., HIF-driven VEGF recruits blood vessels, which bring nutrients that feed tumor metabolism; metabolic changes create vulnerabilities that tumor cells adapt to (like preferring glycolysis); immune infiltration triggers PD-L1 upregulation, which protects tumor cells, etc. Recent high-throughput studies confirm that despite extensive **intratumoral heterogeneity** in mutations, these fundamental pathways remain recurrently perturbed in RCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=Renal%20cell%20carcinoma%20,in%20a%20spatially%20defined%20manner)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=has%20been%20proposed%20%283%20%29,4)), making them attractive targets for therapy and biomarkers for disease monitoring.

## Disease Progression and Pathophysiological Sequence

RCC development typically follows a multi-stage progression:

- **Initiation:** A *triggering genetic event* in a healthy renal epithelial cell provides the first growth advantage. In sporadic ccRCC, this is most often a *“first hit” mutation in one VHL allele*, followed by loss of the second allele (consistent with Knudson’s two-hit hypothesis) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=A%20%E2%80%9Ctwo,takes%20place%20via%20somatic%20mutations)). This can occur via somatic mutation or 3p deletion that removes the VHL locus ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=sporadic%20disease,of%20ccRCC%20cases%20%5E%7B12)). In hereditary cases (Von Hippel–Lindau disease), a germline VHL mutation is present in every cell (first hit) and a somatic second hit in a renal cell precipitates a tumor focus ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=A%20%E2%80%9Ctwo,takes%20place%20via%20somatic%20mutations)). For papillary RCC, initiation might be a MET mutation or trisomy of chromosome 7; for chromophobe RCC, perhaps early loss of multiple chromosomes (causing haploinsufficiency of critical genes) is the initiating event.

- **Clonal Expansion:** The cell with the initiating mutation begins to proliferate abnormally, forming a neoplastic clone in the kidney **tubular epithelium** (often the **proximal convoluted tubule, UBERON:0001285**, for ccRCC and Type 2 pRCC; distal nephron for chromophobe). Early on, the VHL-mutant clone (in ccRCC) experiences *constitutive HIF activation*, leading to a highly vascular microtumor. This gives the small tumor adequate oxygen and nutrient supply via new capillaries (i.e., **angiogenic switch** turned on at inception). Over time, additional driver mutations accumulate in subsets of cells within the tumor – an evolutionary process generating subclones. Common *second hits* in ccRCC impact PBRM1, SETD2, or BAP1 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=has%20been%20proposed%20%283%20%29,4)). The sequence can influence tumor behavior: for example, if a VHL-mutant cell acquires a PBRM1 mutation, the resulting clone might grow relatively slowly (indolent path); if instead it acquires BAP1 mutation, the clone may gain more aggressive traits (high grade, propensity to metastasize) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). This concept is supported by studies showing BAP1-mutant tumors often present with higher grade and worse outcomes than PBRM1-mutants ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). In papillary RCC, after the MET-driven initiation, additional changes like CDKN2A loss or SETD2 mutation can likewise drive progression to higher grade tumors ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=PRCC%20is%20further%20subdivided%20into,8)).

- **Local Growth and Angiogenesis:** As the tumor expands in the kidney, it typically remains encapsulated by the renal capsule initially (Stage I or II if >7cm). Pathophysiologically, the expanding RCC often invades into nearby structures as it grows: it can break through the tubular basement membrane, invade the renal parenchyma and vasculature. A striking feature of RCC is its tendency to invade veins – RCC can grow as a **tumor thrombus in the renal vein and even extend up the inferior vena cava** in advanced cases (this happens because RCC tumor cells find the low-resistance venous space conducive, often facilitated by MMPs and VEGF-induced vessel remodeling). Locally, the tumor induces a fibrous pseudo-capsule and areas of necrosis if outgrowing blood supply. Immune cells infiltrate the tumor margins, sometimes forming lymphoid aggregates – an ongoing battle between tumor and host immune surveillance.

- **Invasion and Metastasis:** Key changes that facilitate metastasis include **epithelial-mesenchymal transition (EMT)** program activation (some RCCs with sarcomatoid differentiation show EMT-like gene expression), secretion of proteases (to degrade extracellular matrix), and continued angiogenesis to enter blood vessels. RCC commonly metastasizes **hematogenously**. The most frequent metastatic sites are the **lungs (approximately 50–70% of metastases)**, **bone (~30%)**, **liver (~20%)**, and **brain (~8%)**, as well as unusual sites like thyroid or skin ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Metastatic%20disease%20,40%20%2C%2047)). The propensity for these sites is partly anatomical (kidney’s high blood flow to lungs) and partly molecular (e.g., CXCR4 chemokine receptor on RCC cells aiding in homing to CXCL12-rich organs like lung and bone). Notably, RCC metastases can be highly vascular lesions too (bleeding risks in lung or bone lesions). The time to metastasis can be variable – about 10% of patients have metastatic disease at diagnosis, and another ~10–20% of initially localized RCC will later metastasize ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=)). Clinically and pathologically, progression is captured by staging (I–IV) and grading systems (historically Fuhrman grade, now WHO/ISUP nucleolar grade). A higher grade reflects more anaplasia, often correlating with molecular changes like TP53 mutations or sarcomatoid morphology. Over the course of progression, RCC cells also often upregulate immune checkpoints (e.g., PD-L1 expression is higher in more advanced or sarcomatoid tumors), helping later-stage tumors to resist immune destruction ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=immune%20response%2C%20leading%20to%20tumor,cell%20receptor)).

- **Tumor Heterogeneity:** A hallmark of RCC progression is branching evolution leading to intratumor heterogeneity (ITH). Different regions of a single RCC may harbor distinct mutations and phenotypes (e.g., one region might have PBRM1 mutation, another BAP1, etc.). This results in **spatial niches** – e.g., hypoxic necrotic center vs. proliferative invasive edge ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=Besides%20genomic%20ITH%2C%20there%20is,tumor%20cell%20proliferation%20in%20this)). The tumor edge tends to have more proliferative activity (high Ki-67 index) than the center ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=includes%20the%20formation%20of%20intratumoral,genetic)), possibly driven by better oxygenation at the periphery and signaling crosstalk with the surrounding stroma. Interestingly, recent evidence suggests that not all genetic mutations have an obvious “functional proxy” at the phenotypic level due to compensatory mechanisms and ITH ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=Unexpectedly%2C%20the%20presence%20of%20a,the%20number%20of%20driver%20mutations)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=In%20the%20present%20proof,and%20precision%20medicine%20in%20RCC)). This complexity means that as RCC progresses, different clones can dominate different metastases or recur after treatment, which is a major challenge for therapy (leading to mixed responses and drug resistance).

- **Late Progression and Resistance:** In advanced metastatic RCC, additional molecular changes often emerge under therapeutic pressure. For instance, prolonged anti-angiogenic therapy can lead tumors to activate alternative angiogenic pathways or become more invasive. Some RCCs undergo *dedifferentiation* to spindle-cell or sarcomatoid carcinoma, which is associated with TP53 mutations and aggressive behavior (this can be viewed as progression to a higher-grade state with loss of original differentiation). RCC can also seed **renal vein tumor thrombi**, which if it propagates can cause Budd-Chiari syndrome or pulmonary emboli (though tumor thrombi are solid). Ultimately, widespread metastases lead to organ dysfunction (e.g., lung failure, bone marrow replacement, etc.). Cachexia (weight loss and muscle wasting, HP:0004326) is common in late stages, likely driven by tumor-secreted cytokines like IL-6 and TNF-α.

In summary, RCC progression is *stepwise*: initiation (often VHL loss) → clonal expansion with angiogenesis → additional hits (PBRM1/BAP1 etc.) → local invasion (driven by molecular changes and microenvironment interactions) → metastasis (via hematogenous spread, facilitated by EMT and angiogenesis) → therapy resistance and further clonal evolution. These stages align with clinical phases from an incidentally detected small tumor to symptomatic advanced disease. The **multi-stage model** is supported by molecular timing studies (e.g., TRACERx Renal) which found that the 3p loss event often occurs years before clinical presentation, with subsequent driver mutations accruing over time ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29656891/#:~:text=Clear%20cell%20renal%20cell%20carcinoma,differences%20in%20age%20incidence%20between)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29656891/#:~:text=most%20common%20structural%20abnormality%20generates,offering%20opportunity%20for%20early%20intervention)). By the time RCC is diagnosed, it may already be an assembly of subclones at various stages of this evolutionary path.

## Phenotypic Manifestations and Clinical Correlations

The disrupted molecular and cellular processes in RCC manifest as specific **clinical phenotypes (Human Phenotype Ontology terms)** and pathological features:

- **Solid Renal Mass on Imaging:** Most RCCs today are discovered incidentally as an asymptomatic renal mass on ultrasound or CT scan ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=How%20Are%20Most%20Renal%20Cell,Carcinomas%20Identified)). The tumor’s hypervascularity often leads to radiologic contrast enhancement. Smaller tumors are often asymptomatic (hence the high rate of incidental detection, ~37–61% ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=How%20Are%20Most%20Renal%20Cell,Carcinomas%20Identified))). As a mass grows, it can cause the classic triad of **flank pain (HP:0003418)**, **hematuria (HP:0000790)**, and a palpable abdominal mass – however, this triad is now uncommon (<10% of cases) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Between%2037,more%20often%20in%20advanced%20disease)). Hematuria results from tumor invasion into the collecting system or renal pelvis, causing bleeding into the urine. Flank pain can result from tumor stretching the renal capsule or invading local nerves, or from hemorrhage into the tumor causing capsular distension. A palpable mass indicates a relatively large tumor typically (> T2 stage). Gross hematuria occurs in <25% of patients at diagnosis and usually indicates tumor involving the urinary collecting system or advanced disease ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Between%2037,more%20often%20in%20advanced%20disease)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=onset%2C%20only%20large%20RCCs%20are,24)).

- **Paraneoplastic Syndromes:** RCC is notorious for causing systemic manifestations unrelated to tumor burden (occurring in ~10–40% of patients) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Paraneoplastic%20syndromes%20occur%20in%2010,with%20RCC%3B%20hepatosplenomegaly%20without%20liver)). These **paraneoplastic syndromes (HP:0002665)** reflect ectopic production of hormones or cytokines by the tumor:
  - **Erythrocytosis (Polycythemia, HP:0001901):** 2–5% of RCC patients develop elevated red blood cell counts ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Common%20paraneoplastic%20manifestations%20include%20fever,Stauffer%20syndrome%2C%20a%20paraneoplastic)). Mechanism: RCC cells (especially VHL-deficient ones) overexpress **EPO (erythropoietin)** under control of HIF-2α ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Common%20paraneoplastic%20manifestations%20include%20fever,Stauffer%20syndrome%2C%20a%20paraneoplastic)). The excess EPO stimulates red blood cell production, leading to ruddy complexion, high hemoglobin, and sometimes hyperviscosity symptoms. This is a direct result of the HIF pathway activation in tumor cells.
  - **Paraneoplastic Hypercalcemia (HP:0003072):** Up to 20–30% of advanced RCC can have high calcium levels ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Paraneoplastic%20syndromes%20occur%20in%2010,with%20RCC%3B%20hepatosplenomegaly%20without%20liver)). Mechanisms: some RCC produce parathyroid hormone-related peptide (PTHrP) which causes calcium release from bone; additionally, extensive osteolytic bone metastases (common in RCC) can exacerbate hypercalcemia. Clinically, this leads to fatigue, confusion, and polyuria/polydipsia.
  - **Non-metastatic Hepatic Dysfunction (Stauffer syndrome):** ~3% of RCC patients present with cholestatic liver dysfunction (elevated alkaline phosphatase, hepatosplenomegaly) in the absence of liver metastases ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypertension%20%283,nephrectomy%20may%20indicate%20residual%20disease)). This is thought to be due to cytokines (like IL-6 or tumor necrosis factor) released by the tumor affecting the liver. Stauffer syndrome can cause jaundice and coagulopathy, but interestingly it often *reverses after nephrectomy or effective treatment* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=cells%20upon%20VHL%20inactivation.,nephrectomy%20may%20indicate%20residual%20disease)), confirming its paraneoplastic nature.
  - **Anemia and Cachexia:** Anemia (low RBC count) is reported in 20–50% of RCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Paraneoplastic%20syndromes%20occur%20in%2010,with%20RCC%3B%20hepatosplenomegaly%20without%20liver)), often anemia of chronic disease from inflammation (elevated IL-6 drives hepcidin up, reducing iron availability). This coexists paradoxically with erythrocytosis in some patients (different clones might produce EPO vs. IL-6). Cachexia (weight loss, muscle wasting) is common in advanced RCC due to tumor-produced pro-inflammatory cytokines (IL-6, TNF-α, etc.) and can be severe, contributing to fatigue and weakness.
  - **Fever and Night Sweats:** Low-grade fever (in about 8% of patients) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Paraneoplastic%20syndromes%20occur%20in%2010,with%20RCC%3B%20hepatosplenomegaly%20without%20liver)) and drenching sweats can occur due to cytokine release (RCC was historically known as a cause of “fever of unknown origin”). IL-6 is again a suspected mediator, and successful treatment often abates these fevers.
  - **Thrombocytosis (high platelets):** 8–12% of patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Paraneoplastic%20syndromes%20occur%20in%2010,with%20RCC%3B%20hepatosplenomegaly%20without%20liver)) have elevated platelet counts, likely from IL-6 driven megakaryocyte stimulation. This can increase risk of venous thromboembolism in an already pro-thrombotic malignancy.

- **Hypertension (HP:0000822):** Approximately 15–20% of RCC patients have new-onset or worsening high blood pressure ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Common%20paraneoplastic%20manifestations%20include%20fever,Stauffer%20syndrome%2C%20a%20paraneoplastic)). This can be multifactorial: renal tumors can overproduce renin (rarely), but more commonly chronic kidney disease due to tumor or nephrectomy plays a role, and high circulating VEGF can increase endothelial dysfunction. Also, anti-VEGF therapies for RCC cause hypertension as a side effect by decreasing nitric oxide in vessels ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=match%20at%20L613%20Patients%20treated,77%E2%80%9379%7D%20Table%202%20summarizes)). In some cases, removing the kidney tumor (nephrectomy) actually improves blood pressure, implying a tumor-secreted pressor substance.

- **Macroscopic Pathology:** RCC tumors are typically *golden-yellow* (due to high lipid content in clear cells) with areas of hemorrhage and necrosis. The clear cells have a high glycogen and cholesterol content (reflecting metabolic changes). Papillary RCC often appears tan-brown and is softer, with frequent hemorrhagic cystic areas and papillary structures microscopically. Chromophobe RCC is a pale beige-tan and has distinct plant-cell-like histology with prominent cell membranes and perinuclear halos (due to abnormal mitochondria). The pathophysiology (lipid accumulation in clear cell, papillae formation in papillary, etc.) directly correlates with these appearances – e.g., clear cells accumulate lipids because of HIF-driven lipid uptake and abnormal metabolism; papillary tumors form papillae likely due to their cell of origin (distal convoluted tubule epithelium) and growth pattern.

- **Histological Phenotypes:** On microscopy, ccRCC cells have *clear cytoplasm* because glycogen and lipid are dissolved on slide prep – a key phenotypic hallmark linked to the metabolic reprogramming discussed. They also often express **carbonic anhydrase IX (CAIX)** diffusely on immunohistochemistry ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=RCC%20arises%20from%20epithelial%20cells,13)), a direct HIF1 target and diagnostic marker of ccRCC. Papillary RCC cells often have eosinophilic cytoplasm and grow in a papillary architecture with fibrovascular cores; type 1 papillary has small basophilic cells (often MET-driven, indolent), while type 2 has large eosinophilic cells (often FH or other mutations, aggressive). Chromophobe RCC cells are polygonal with pale/reticulated cytoplasm and a perinuclear clearing; they often show *multiple chromosomal losses* cytogenetically, explaining the “chromophobic” (pale) appearance due to loss of pigmentation organelles and other molecules. Each subtype’s phenotype reflects its genotype: e.g., FH-mutant RCC (HLRCC) often has intensely eosinophilic, large cells with massive nuclei (very high-grade appearance), corresponding to its highly deranged metabolism and aggressive behavior.

- **Symptomatology of Metastases:** Metastatic spread produces symptoms based on organ involved. *Lung metastases* (most common) cause cough, hemoptysis, or dyspnea. *Bone metastases* cause bone pain (HP:0002653) and pathologic fractures; RCC bone lesions are often osteolytic (consistent with hypercalcemia). *Brain metastases* cause headaches, seizures, or focal neurologic deficits. Occasionally, unusual sites like thyroid metastases may present as a thyroid nodule, etc. RCC’s ability to metastasize widely is due to its rich blood supply and expression of adhesion molecules enabling tumor cell lodging in various tissues. Because RCC metastases can appear years after nephrectomy (even >5–10 years later in some cases), long-term follow-up is needed – reflecting that dormant microscopic metastatic clones can exist and later get activated.

- **Laboratory and Biomarker Correlations:** Aside from clinical phenotypes, certain lab abnormalities mirror the pathophysiology: Elevated serum *LDH* and *C-reactive protein (CRP)* are adverse prognostic markers in RCC, indicating high tumor metabolic activity (LDH from high glycolysis) and inflammation (CRP from IL-6). These are included in prognostic risk scores ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=,0642%20%5BDOI%5D%20%5BPubMed%5D%20%5BGoogle)). High serum CAIX or VEGF levels can sometimes be detected and correspond to tumor burden/angiogenesis, though they are not used routinely. Molecular signatures (mRNA expression profiles) have identified subsets of ccRCC, such as an “angiogenic” subtype vs. an “immune” subtype, linking phenotype to dominant pathophysiology: e.g., tumors with high VEGF and angiogenesis genes (often PBRM1-mutant) versus tumors with high immune checkpoint expression and inflammation (often BAP1-mutant) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L247%20,1%2C%2034)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). These differences manifest clinically in how tumors appear on scans (more vs. less enhancement), their growth rate, and their response to therapies (angiogenesis-high tumors respond well to VEGF inhibitors, immune-high tumors may respond better to immunotherapy).

In conclusion, the **clinical phenotype of RCC** – from asymptomatic small tumor to systemic paraneoplastic syndromes – is intimately tied to its underlying molecular pathology. The **angiogenic drive** explains its vascular nature and imaging appearance; the **metabolic shifts** explain the clear cell morphology and systemic effects (weight loss, etc.); the **ectopic hormone production** explains syndromes like erythrocytosis and hypercalcemia; and the **immune evasion** explains why immunotherapy is needed for cure in many advanced cases. Clinicians leverage this knowledge: for example, the presence of paraneoplastic syndromes or certain lab changes can hint at RCC even before imaging confirms it, and conversely effective treatment often leads to resolution of these syndromes (a striking validation of the causal pathophysiology) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=cells%20upon%20VHL%20inactivation.,nephrectomy%20may%20indicate%20residual%20disease)).

## Recent Developments and Expert Insights

Advances in the past few years have deepened our understanding of RCC pathophysiology and led to new interventions:

- **Molecular Subclassification:** The 2022 WHO classification of renal tumors now recognizes over 20 subtypes of RCC, many defined by specific molecular alterations ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=into%20papillary%20RCC%20and%20classified,14)). For example, *FH-deficient RCC*, *SDH-deficient RCC*, *TFE3/Xp11 translocation RCC*, and others are distinguished by unique pathogenesis. This granularity ensures patients receive tailored surveillance and therapy (e.g., FH-deficient RCC mandates aggressive treatment even if the tumor is small, due to high metastatic potential ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4447120/#:~:text=the%20Warburg%20Effect%20in%20Cancer,Fumarate%20hydratase%3A%20the%20HLRCC))).

- **Targeted Therapies Evolving:** Building on the VHL/HIF pathway knowledge, HIF2α inhibitors (like **belzutifan**) have emerged. As of 2023, belzutifan showed a 22% response rate in refractory metastatic RCC and significantly prolonged progression-free survival compared to an mTOR inhibitor ([www.merck.com](https://www.merck.com/news/fda-approves-mercks-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-rcc-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki/#:~:text=The%20approval%20is%20based%20on,6%29%20for%20everolimus)). This drug, by directly blocking the HIF transcriptional driver, represents a *new class of therapy directly addressing RCC’s core pathophysiology*. Similarly, *MET inhibitors* (e.g., savolitinib) are being tested in MET-driven papillary RCC and showing promise (early trials indicate objective responses, particularly in MET-mutated tumors). Combination therapies are also a focus: e.g., combining glutaminase inhibitors with immunotherapy to exploit metabolic vulnerabilities while stimulating immune attack ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L356%20In%20addition%2C,cabozantinib%20in%20separate%20clinical%20trials)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=In%20addition%2C%20the%20glutaminase%20inhibitor,cabozantinib%20in%20separate%20clinical%20trials)).

- **Immune Microenvironment Research:** Cutting-edge single-cell sequencing and high-plex imaging of RCC tumors have mapped the immune landscape in fine detail. A 2022 study by De Filippis *et al.* identified distinct immune microenvironment patterns in ccRCC, such as an “immune-inflamed, exhausted T-cell” niche vs. an “immune-cold, angiogenic” niche ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=%5BPubMed%5D%20%5BGoogle%20Scholar%5D%20,C%2C%20Hermanns%20T%2C%20et%20al)). These correlate with mutations (e.g., PBRM1-mutant tumors were more immune-infiltrated in some reports) and could guide immunotherapy use. Moreover, novel immunotherapies beyond PD-1 are in trials (e.g., HIF-2α inhibitors combined with PD-1 blockade, CAR-T cells targeting CAIX or other RCC antigens, etc.).

- **Genomic Heterogeneity and Precision Medicine:** The TRACERx Renal consortium (Turajlic *et al.*, 2018) provided detailed timelines of RCC evolution. One striking finding was that the average ccRCC has ~4 driver events, and if a clone acquires all needed drivers early (VHL, + others), it can metastasize rapidly, whereas if evolution is more branched, metastasis may occur later or not at all ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29656891/#:~:text=most%20common%20structural%20abnormality%20generates,offering%20opportunity%20for%20early%20intervention)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29656891/#:~:text=or%20adolescence%2C%20generally%20as%20the,offering%20opportunity%20for%20early%20intervention)). This is spawning research into **molecular prognostics**: for example, testing tumors for co-mutations like BAP1 vs. PBRM1 can stratify patients’ risk of aggressive disease ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). Efforts are underway to integrate genomic data with clinical nomograms to enhance prognostic scoring and perhaps to allocate therapies (though, as one 2023 study cautioned, genotype-phenotype correlations aren’t always straightforward due to functional heterogeneity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=In%20the%20present%20proof,and%20precision%20medicine%20in%20RCC))).

- **Expert Commentary:** In a 2019 *Nature Reviews* piece, Dr. Robert Motzer and colleagues described RCC’s therapeutic progress as moving “from the dark age to the golden age” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=,doi)), thanks to pathophysiology-driven drug development. They highlight that understanding VHL/HIF led to VEGF inhibitors, understanding immune evasion led to checkpoint inhibitors, and ongoing research into metabolism and epigenetics will likely yield the next breakthroughs ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=Urol,doi)). Reflecting on combination therapies, experts note that current first-line regimens (PD-1 immunotherapy + VEGF-TKI) are effectively targeting both the immune system and angiogenesis – **tackling two key hallmarks of RCC** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=The%20therapeutic%20landscape%20of%20RCC,advances%2C%20a%20substantial%20proportion%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=and%20the%20current%20standard%20of,ultimately%20experience%20malignant%20progression%20and)). Nonetheless, they also emphasize that cures are elusive in metastatic RCC; thus, research is focusing on overcoming resistance (e.g., preventing or rechallenging VEGF resistance by alternating therapies, targeting T cell exhaustion pathways, etc.). 

- **Statistics and Outcomes:** Epidemiologically, RCC incidence worldwide continues to rise slowly (~1–2% per year), but mortality is dropping (~2% per year in the US) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=worldwide%2C%20with%20more%20than%20179,due%20to%20improvements%20in%20therapy)), which is attributed to earlier detection and better therapies. In 2023, an estimated 81,800 new RCC cases were diagnosed in the US ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Renal%20cell%20carcinoma%20,Box)). The 5-year survival for localized RCC (confined to kidney) exceeds 90%, while for metastatic RCC it remains around 13%–30% in modern series ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Stage%20%20,27%E2%80%9328)). The pathophysiological understanding has directly contributed to this improvement: for example, adjuvant immunotherapy (pembrolizumab) after nephrectomy improves disease-free survival in high-risk cases ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=Systemic%20treatment%20is%20effective%20in,patients%20with%20RCC%20after%20nephrectomy)), and this strategy stems from recognizing that micrometastatic RCC can be tackled by ramping up the immune system early. 

In summary, **renal cell carcinoma pathophysiology** encompasses a web of molecular and cellular derangements – principally involving **hypoxia sensing, angiogenesis, chromatin/tumor suppressor alterations, metabolic shifts, and immune interactions** – that together drive the initiation, growth, and spread of the tumor. Our current treatments (surgery, VEGF inhibitors, mTOR inhibitors, immune checkpoint blockers, HIF2 inhibitors, etc.) are all rooted in these pathogenic mechanisms. Ongoing research (with an emphasis on 2023–2024 findings) is further unraveling RCC’s complexity, aiming to personalize therapy (based on genetic drivers and immune profile) and improve outcomes. As one recent review noted, “insights into the molecular pathogenesis of RCC have led to the development of therapies that target its underlying pathophysiology and immunobiology” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=prevalence%20of%202.3,Box)), a testament to how understanding disease mechanisms translates into clinical advances. Each new discovery – whether a gene mutation, a metabolic dependency, or an immune escape mechanism – adds a piece to the puzzle, bringing us closer to fully conquering this challenging cancer.

**References:**

1. Rose TL & Kim WY. *Renal Cell Carcinoma.* **JAMA. 2024;332(12):1001–1010**. PMID: 39196544 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=The%203%20dominant%20histological%20subtypes,3p%2C%20home%20to%20VHL%2C%20as)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11790279/#:~:text=hypoxia%20response%20through%20the%20VHL,promoting)). (Key review of RCC epidemiology, genetics, pathophysiology, and treatment)  
2. Nabi S *et al.* *Renal cell carcinoma: a review of biology and pathophysiology.* **F1000Research. 2018;7:307**. PMID: 29568504 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=Multiple%20risk%20factors%20for%20RCC,7)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=The%20most%20common%20genetic%20alteration,%5E%7B8)). (Detailed review of RCC genetic alterations, VHL/HIF pathway, and immune environment)  
3. Turajlic S *et al.* *Tracking renal cancer evolution (TRACERx Renal).* **Cell. 2018;173(3):595-610.e11**. PMID: 29625050 ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29656891/#:~:text=Clear%20cell%20renal%20cell%20carcinoma,differences%20in%20age%20incidence%20between)). (Study of ccRCC intratumoral heterogeneity and evolutionary trajectories, highlighting ubiquitous 3p loss and subclonal diversification)  
4. Rhoades Smith KE & Bilen MA. *A review of papillary renal cell carcinoma and MET inhibitors.* **Kidney Cancer. 2019;3(3):151–161**. PMID: 31867475 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6918905/#:~:text=PRCC%20is%20further%20subdivided%20into,8)). (Overview of papillary RCC subtypes, MET-driven pathogenesis, and targeted therapies)  
5. Sudarshan S *et al.* *Fumarate hydratase deficiency in renal cancer induces HIF-1α stabilization by ROS.* **Mol Cell Biol. 2009;29(15):4080–4090**. PMID: 19470762 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2715796/#:~:text=in%20several%20model%20systems%2C%20and,following%20experimental%20abrogation%20of%20FH)). (Experimental study showing how FH loss leads to pseudohypoxia and metabolic reprogramming in RCC)  
6. Choueiri TK *et al.* *Belzutifan for VHL disease-associated RCC and advanced RCC.* – FDA Approval Press Release, Dec 14, 2023 ([www.merck.com](https://www.merck.com/news/fda-approves-mercks-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-rcc-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki/#:~:text=The%20approval%20is%20based%20on,6%29%20for%20everolimus)) ([www.merck.com](https://www.merck.com/news/fda-approves-mercks-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-rcc-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki/#:~:text=%E2%80%9CDespite%20recent%20progress%20in%20the,%E2%80%9D)). (Announces HIF-2α inhibitor approval; contains expert commentary on its significance)  
7. **Cancer Genome Atlas Research Network.** *Comprehensive molecular characterization of clear cell RCC.* **Nature. 2013;499(7456):43–49**. PMID: 23792563 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061699/#:~:text=,Google%20Scholar)). (Landmark TCGA study defining the key mutated genes and pathways in ccRCC)  
8. Şenbabaoğlu Y *et al.* *Tumor immune microenvironment in ccRCC: prognostic mRNA signatures.* **Genome Biol. 2016;17:231**. PMID: 27884208 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L247%20,1%2C%2034)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L564%20,z%20%5BDOI%5D%20%5BPMC)). (Genomic analysis linking immune infiltration patterns with outcomes in RCC)  
9. Brugarolas J. *PBRM1 and BAP1 as novel targets for RCC.* **Cancer J. 2013;19(4):324–332**. PMID: 23989106 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=introduction%20of%20PBRM,23%2C%2024)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5850086/#:~:text=match%20at%20L176%20BRCA1,plays%20a%20role%20in%20the)). (Discusses PBRM1/BAP1 tumor suppressors and their clinical impact in RCC)  
10. Linehan WM & Ricketts CJ. *The metabolic basis of kidney cancer.* **Semin Cancer Biol. 2013;23(1):46–55**. PMID: 23123217. (Explores how metabolic alterations like VHL/HIF, FH, SDH drive RCC; introduces concept of oncometabolites)  

*(All links and citations accessed 2023–2024; URLs provided where applicable. Dates in references indicate publication year.)*